OncoCyte changes name to Insight Molecular Diagnostics

Insight Molecular Diagnostics (IMDX) announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq Capital Market, will begin trading under the new stock symbol “IMDX,” effective before the market opens on Wednesday, June 18, 2025. The new name more accurately reflects the Company’s expanded strategic direction and diversified product portfolio. Although oncology remains a key area of innovation, the new name better reflects its expanded strategic direction and diversified portfolio, including a focus on transplant medicine. The Company remains committed to its goal of delivering a clinically available molecular diagnostic kit to expand testing access for kidney transplant patients, which it anticipates will unlock value in the estimated $1B addressable market for transplant rejection testing. So far in 2025, iMDx believes it has made disciplined and focused progress toward this goal, executing the critical steps required to transition from product development to commercialization. To support these efforts, iMDx is relocating its principal executive office from Irvine, California to Nashville, Tennessee – home to the Company’s CLIA-certified lab and a growing hub for healthcare innovation. The move reflects a strategic alignment of operations and proximity to both core infrastructure and industry talent. The Company also expects to maintain its laboratory and research and development center in Gottingen, Germany. The new name leverages iMDx’s existing rights to the name Insight Genetics, which it acquired in 2020. In addition, the Company’s CLIA-certified and CAP-accredited lab in Nashville launched as “Insight Molecular Labs,” in 2013 and maintains that name today. The Company’s new iMDx logo features DNA banding patterns on the “i,” as well as a centered MD – for medical doctor, reflecting iMDx’s healthcare provider-centric philosophy. Further, “Dx” is a common industry abbreviation for both diagnostics and diagnosis. As part of the rebranding initiative, iMDx is also retiring the VitaGraft name and unifying its transplant diagnostics under the GraftAssure brand. The updated nomenclature will better align with each product’s regulatory classification and intended use: GraftAssureCore – The Company’s lab-developed test, currently reimbursed by CMS and performed at its CLIA-certified laboratory in Nashville. GraftAssureIQ – An RUO kit intended for non-clinical applications and clearly labeled as such. GraftAssureDx – The in vitro diagnostic kit currently in development for use in clinical decision-making, which the Company intends to submit for FDA authorization.